Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14966410 | 0.88 | GPR119 (0.40) | GPR119KCNH2 | |
| SCHEMBL14966714 | 0.88 | GPR119 (0.35) | GPR119NR1H2NR1H3 | |
| SCHEMBL14978705 | 0.84 | GPR119 (0.39) | GPR119KCNH2 | |
| SCHEMBL14965997 | 0.80 | GPR119 (0.42) | GPR119KCNH2CYP3A4NR1H2NR1H3 | |
| SCHEMBL14966416 | 0.79 | KCNH2 (0.45) | GPR119KCNH2NR1H2NR1H3 | |
| SCHEMBL16172053 | 0.78 | TP53 (0.42) | GPR119KCNH2CYP3A4OPRM1 | |
| SCHEMBL14978690 | 0.77 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL2599393 | 0.77 | GPR119 (0.43) | GPR119KCNH2CYP3A4 | |
| SCHEMBL12186171 | 0.77 | GPR119 (0.43) | GPR119KCNH2CYP3A4 | |
| SCHEMBL2598425 | 0.77 | GPR119 (0.42) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | GPR119 1/4885KCNH2 1308/4885CYP3A4 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.